Developer docs
API playgroundTry for free, no card

Search company profiles

Ad Scientiam

Full company profile

uuid0003a29

Namestring
Ad Scientiam
Legal namestring
Ad Scientiam SAS
Websiteurl
adscientiam.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Ad Scientiam is a French digital health company founded in 2013 that designs, validates, and commercializes Software as a Medical Device (SaMD) solutions measuring disease progression through digital biomarkers derived from continuous smartphone sensor data. Headquartered at the iPEPS Healthtech Hub of the Institut du Cerveau in Paris and born at Pitié-Salpêtrière hospital, the company targets pharmaceutical companies and patients living with serious neurological and chronic diseases, with its flagship MSCopilot® being the first CE-marked Class IIa SaMD for real-life self-assessment of multiple sclerosis (CE marked June 2025, FDA 510(k) registered 2025–2026). Its proprietary algorithms process 350+ digital biomarkers covering walking, vision, dexterity, and cognition, with outputs clinically validated against EDSS and MSFC-4 gold standards across the MS-DETECT (243 patients) and MS-FLOWER (62 patients in four US centers) studies.

The company operates a dual-track business model: MSCopilot is provided free of charge to patients and healthcare professionals via iOS and Android app stores, while revenue is generated through B2B licensing and clinical study services to pharmaceutical partners including Sanofi, Merck KGaA, and Vertex Pharmaceuticals. Ad Scientiam secured €5 million in funding from TechLife Capital in November 2025 to support expansion of its digital biomarker portfolio, entry into new therapeutic areas (including a generalized myasthenia gravis program with Merck KGaA launching 2026), and enhanced commercialization. The company is expanding its product surface with MuCopilot® for cystic fibrosis (70-patient clinical study planned, targeting Class IIa certification), opening a US subsidiary, and pursuing geographic expansion into the US and Germany. The company maintains ISO 13485 certification, GDPR-compliant data practices on EU-hosted Azure infrastructure, and CE/FDA regulatory clearances that create meaningful barriers to entry in the MS digital biomarker space.

Short descriptiontext

Ad Scientiam is a French digital health company developing CE-marked and FDA-registered Software as a Medical Device (SaMD) that uses smartphone sensors and proprietary algorithms to generate clinically validated digital biomarkers for monitoring multiple sclerosis, cystic fibrosis, and other serious diseases, serving pharmaceutical companies and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital biomarkers, medical device software, clinical trial technology, remote patient monitoring, multiple sclerosis software
Industry4 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAN
DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code4 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
  • Medical and Diagnostic Laboratories62151
  • Computer Systems Design and Related Services54151
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
  • Services-Health Services8000
Product category
Medical Device Software (Digital Health)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1B2B Licensing to Pharmaceutical Companies
TypeSubscription Recurring
Description

Ad Scientiam generates revenue by providing its digital biomarker platforms (MSCopilot, MuCopilot) to pharmaceutical companies for use in clinical trials, drug development, and post-marketing surveillance. The company is used in several clinical studies and partners with pharma for regulatory-grade real-world data collection.

2Clinical Study Services
TypeProfessional Services
Description

The company conducts clinical studies on behalf of pharmaceutical partners, providing digital measurement solutions and regulatory-grade data. Multiple studies are referenced including MS-DETECT, MS-FLOWER, and studies for Merck KGaA and Vertex.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Free for patients and healthcare professionals
ModelFreemiumBilling cadenceMonthly
Notes

MSCopilot is provided free of charge to patients and healthcare professionals. Revenue is generated through B2B arrangements with pharmaceutical companies.

GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1MSCopilot®
Description

First CE-marked software medical device for real-life self-assessment of Multiple Sclerosis patients. Captures over 350 digital biomarkers on physiological and behavioral characteristics via smartphone. Currently has over 3,500 users.

adscientiam.com
+1 more record
Core offering1 text field

Ad Scientiam designs, validates, and commercializes Software as a Medical Device (SaMD) digital biomarkers that continuously measure disease progression in real-life conditions using smartphone sensor data processed by proprietary algorithms. Its flagship product MSCopilot® is a CE-marked (Class IIa) and FDA 510(k)-registered SaMD for self-assessment of Multiple Sclerosis patients, capturing more than 350 digital biomarkers across walking, vision, dexterity, and cognition. The portfolio also includes MuCopilot® for at-home cystic fibrosis monitoring and pipeline work in generalized myasthenia gravis with Merck KGaA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • MSCopilot digital biomarkers correlate significantly with clinical scores MSFC-4 and EDSS in MS-DETECT study (243 patients, interim analysis)
+2 more records
Product overview1 text field

Ad Scientiam is a pioneer in digital biomarkers, designing, validating, and implementing Software as a Medical Devices (SaMD) that continuously measure disease progression in real life. The company's portfolio includes MSCopilot® (for Multiple Sclerosis, launched 2018, CE/FDA cleared) and MuCopilot® (for Cystic Fibrosis, in development). Both products use patients' smartphones to collect sensor data transformed by proprietary algorithms into clinically-validated digital biomarkers. Results are shared with healthcare professionals via secure dashboards. The company focuses on neuroscience (MS, neuromuscular diseases), mental disorders (treatment-resistant depression), and rare diseases (cystic fibrosis, hemophilia).

Product and service2 records
1MSCopilot®
CategoryMedical Device Software - Digital Biomarker SaMD
Description

Software as a Medical Device (SaMD) for real-life self-assessment of Multiple Sclerosis patients. Uses patients' smartphones to capture more than 350 digital biomarkers on physiological and behavioral characteristics, including walking, visual acuity, dexterity, and cognition, then processes them through proprietary algorithms to generate scores that correlate with clinical gold standards (MSFC-4, EDSS). Results are shared via secure dashboard with healthcare professionals to support clinical decision-making. CE-marked (Class IIa) and FDA 510(k) registered. Used by 3,500+ patients.

2MuCopilot®
CategoryMedical Device Software - Digital Biomarker SaMD
Description

Software as a Medical Device (SaMD) dedicated to disease monitoring for cystic fibrosis. Measures respiratory function (phonation time), nocturnal cough, and endurance via smartphone sensors alone, enabling at-home monitoring between clinic visits. Currently in clinical development with a planned 70-patient study to correlate home measurements with clinical standards, developed in partnership with Vertex Pharmaceuticals and Société Française de la Mucoviscidose.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Ad Scientiam and Merck KGaA are collaborating on a prospective, multicenter pilot study starting in 2026 across several European countries to evaluate an investigational software medical device combining a mobile application, wearable, and ePROs to collect digital measures in real-life unsupervised conditions for monitoring generalized myasthenia gravis (gMG).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sanofi supported the MS-FLOWER pilot (62 MS patients across 4 US centers in Austin, St. Louis, Oklahoma City, New Orleans) and the MS-DETECT (NCT05816122) international clinical study. First results of MS-FLOWER to be presented at AAN 2026. Sanofi is a key partner in clinical validation of MSCopilot.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vertex Pharmaceuticals partnered with Ad Scientiam and the Société Française de Mucoviscidose on the Mucolab project, an ambitious innovation to improve at-home follow-up of cystic fibrosis patients through new respiratory digital biomarkers. Vertex is a global biotech company focused on cystic fibrosis treatments.

4Société Française de Mucoviscidose (Cystic Fibrosis French Society)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

The Société Française de Mucoviscidose partnered with Ad Scientiam and Vertex Pharmaceuticals on the Mucolab project to develop respiratory digital biomarkers for at-home cystic fibrosis monitoring.

adscientiam.com
Strategic tierSupportingTypeTechnology or Integration
Description

Ad Scientiam's website and data infrastructure are hosted on Microsoft's Azure cloud offering, geographically located within the European Union. Microsoft France is a certified health data host.

Strategic tierSupportingTypeOthers
Description

BSI is the Notified Body that granted Ad Scientiam its ISO 13485 'Medical devices - Quality management system' certification in August 2020.

Strategic tierSupportingTypeOthers
Description

All Ad Scientiam Medical Devices are declared to the ANSM before being made available on the French market, in accordance with French medical device regulations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medable provides decentralized clinical trial technology and eCOA/ePRO solutions used by pharma sponsors to capture patient data outside clinic visits. Directly comparable to Ad Scientiam's B2B pharma clinical-trial enablement model and target customer base.

TypeDirect peer
Description

Koneksa develops digital biomarkers and remote patient monitoring tools used in clinical trials across therapeutic areas including neuroscience. Closely aligned to Ad Scientiam in technology (wearable/sensor-derived biomarkers), customer base (pharma), and validation model (clinical correlations).

TypeDirect peer
Description

VivoSense specializes in wearable sensors and digital endpoints for clinical trials and drug development, with regulatory-grade sensor data analytics. Direct competitor in digital biomarker/SaMD solutions sold to pharma sponsors.

TypeDirect peer
Description

Evidation Health operates a digital health measurement platform that generates real-world evidence and digital biomarkers from consumer devices for pharma and life sciences clients. Highly comparable business model of consumer-grade data → regulatory-grade pharma evidence.

TypeEmerging player
Description

Aparito provides remote patient monitoring and digital endpoint solutions for rare disease and specialty pharma clinical trials. Comparable in disease-monitoring SaMD positioning and pharma B2B model, though focused on smaller patient populations.

TypeEmerging player
Description

uMotif offers a patient data capture platform (ePRO, eCOA) used in clinical trials across therapeutic areas. Adjacent peer in the decentralized clinical trial enablement space, with similar pharma customer base and disease-monitoring use cases.

TypeBroad incumbent
Description

Roche operates a broad digital health portfolio including Flatiron Health (oncology real-world evidence) and mySugr (diabetes monitoring). As a major MS drug manufacturer and Ad Scientiam trust-signal partner, Roche represents both a potential customer and a competitive threat via in-house digital biomarker programs.

TypeBroad incumbent
Description

Biogen is a leading MS therapeutics company and listed as a trust-signal partner of Ad Scientiam. Competes indirectly through its own MS digital health initiatives and is simultaneously a potential enterprise customer for Ad Scientiam's MS monitoring solutions.

TypeBroad incumbent
Description

Novartis operates digital biomarker and decentralized trial programs through its pharma R&D organization and partners like Science 37. Comparable in disease area (MS via Kesimpta) and broad SaMD ambitions.

TypeBroad incumbent
Description

Clario (formed via ERT-Bioclinica merger) is a major provider of clinical trial endpoint technologies including eCOA, imaging, and digital biomarkers. Represents the broad incumbent player in the same pharma B2B SaMD-for-clinical-trials category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ad Scientiam

Medical Device Software (Digital Health)adscientiam.com

Ad Scientiam is a French digital health company developing CE-marked and FDA-registered Software as a Medical Device (SaMD) that uses smartphone sensors and proprietary algorithms to generate clinically validated digital biomarkers for monitoring multiple sclerosis, cystic fibrosis, and other serious diseases, serving pharmaceutical companies and patients.

What Ad Scientiam does

Ad Scientiam is a French digital health company founded in 2013 that designs, validates, and commercializes Software as a Medical Device (SaMD) solutions measuring disease progression through digital biomarkers derived from continuous smartphone sensor data. Headquartered at the iPEPS Healthtech Hub of the Institut du Cerveau in Paris and born at Pitié-Salpêtrière hospital, the company targets pharmaceutical companies and patients living with serious neurological and chronic diseases, with its flagship MSCopilot® being the first CE-marked Class IIa SaMD for real-life self-assessment of multiple sclerosis (CE marked June 2025, FDA 510(k) registered 2025–2026). Its proprietary algorithms process 350+ digital biomarkers covering walking, vision, dexterity, and cognition, with outputs clinically validated against EDSS and MSFC-4 gold standards across the MS-DETECT (243 patients) and MS-FLOWER (62 patients in four US centers) studies.

The company operates a dual-track business model: MSCopilot is provided free of charge to patients and healthcare professionals via iOS and Android app stores, while revenue is generated through B2B licensing and clinical study services to pharmaceutical partners including Sanofi, Merck KGaA, and Vertex Pharmaceuticals. Ad Scientiam secured €5 million in funding from TechLife Capital in November 2025 to support expansion of its digital biomarker portfolio, entry into new therapeutic areas (including a generalized myasthenia gravis program with Merck KGaA launching 2026), and enhanced commercialization. The company is expanding its product surface with MuCopilot® for cystic fibrosis (70-patient clinical study planned, targeting Class IIa certification), opening a US subsidiary, and pursuing geographic expansion into the US and Germany. The company maintains ISO 13485 certification, GDPR-compliant data practices on EU-hosted Azure infrastructure, and CE/FDA regulatory clearances that create meaningful barriers to entry in the MS digital biomarker space.

Ad Scientiam firmographics

Firmographics
Name
Ad Scientiam
Legal name
Ad Scientiam SAS
Website
https://adscientiam.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Ad Scientiam is a French digital health company developing CE-marked and FDA-registered Software as a Medical Device (SaMD) that uses smartphone sensors and proprietary algorithms to generate clinically validated digital biomarkers for monitoring multiple sclerosis, cystic fibrosis, and other serious diseases, serving pharmaceutical companies and patients.
Ownership category
akta.pro rank

Ad Scientiam industry classification

Industry
Product category
Medical Device Software (Digital Health)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Medical and Diagnostic Laboratories (62151), Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAN
DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital biomarkers
  • Medical device software
  • Clinical trial technology
  • Remote patient monitoring
  • Multiple sclerosis software

Where Ad Scientiam is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Ad Scientiam business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. B2B Licensing to Pharmaceutical Companies: Ad Scientiam generates revenue by providing its digital biomarker platforms (MSCopilot, MuCopilot) to pharmaceutical companies for use in clinical trials, drug development, and post-marketing surveillance. The company is used in several clinical studies and partners with pharma for regulatory-grade real-world data collection.
  2. Clinical Study Services: The company conducts clinical studies on behalf of pharmaceutical partners, providing digital measurement solutions and regulatory-grade data. Multiple studies are referenced including MS-DETECT, MS-FLOWER, and studies for Merck KGaA and Vertex.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree for patients and healthcare professionals

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Ad Scientiam product offering

Product offering

Core offering

Ad Scientiam designs, validates, and commercializes Software as a Medical Device (SaMD) digital biomarkers that continuously measure disease progression in real-life conditions using smartphone sensor data processed by proprietary algorithms. Its flagship product MSCopilot® is a CE-marked (Class IIa) and FDA 510(k)-registered SaMD for self-assessment of Multiple Sclerosis patients, capturing more than 350 digital biomarkers across walking, vision, dexterity, and cognition. The portfolio also includes MuCopilot® for at-home cystic fibrosis monitoring and pipeline work in generalized myasthenia gravis with Merck KGaA.

Product overview

Ad Scientiam is a pioneer in digital biomarkers, designing, validating, and implementing Software as a Medical Devices (SaMD) that continuously measure disease progression in real life. The company's portfolio includes MSCopilot® (for Multiple Sclerosis, launched 2018, CE/FDA cleared) and MuCopilot® (for Cystic Fibrosis, in development). Both products use patients' smartphones to collect sensor data transformed by proprietary algorithms into clinically-validated digital biomarkers. Results are shared with healthcare professionals via secure dashboards. The company focuses on neuroscience (MS, neuromuscular diseases), mental disorders (treatment-resistant depression), and rare diseases (cystic fibrosis, hemophilia).

Differentiator

Problem solved

Functional benefit

Brands

  • MSCopilot®: First CE-marked software medical device for real-life self-assessment of Multiple Sclerosis patients. Captures over 350 digital biomarkers on physiological and behavioral characteristics via smartphone. Currently has over 3,500 users.
  • MuCopilot®

Products and services

  • MSCopilot® Software as a Medical Device (SaMD) for real-life self-assessment of Multiple Sclerosis patients. Uses patients' smartphones to capture more than 350 digital biomarkers on physiological and behavioral characteristics, including walking, visual acuity, dexterity, and cognition, then processes them through proprietary algorithms to generate scores that correlate with clinical gold standards (MSFC-4, EDSS). Results are shared via secure dashboard with healthcare professionals to support clinical decision-making. CE-marked (Class IIa) and FDA 510(k) registered. Used by 3,500+ patients.
  • MuCopilot® Software as a Medical Device (SaMD) dedicated to disease monitoring for cystic fibrosis. Measures respiratory function (phonation time), nocturnal cough, and endurance via smartphone sensors alone, enabling at-home monitoring between clinic visits. Currently in clinical development with a planned 70-patient study to correlate home measurements with clinical standards, developed in partnership with Vertex Pharmaceuticals and Société Française de la Mucoviscidose.

Quantifiable outcome

  • MSCopilot digital biomarkers correlate significantly with clinical scores MSFC-4 and EDSS in MS-DETECT study (243 patients, interim analysis)
  • +2 more outcomes

Companies that use Ad Scientiam

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Ad Scientiam technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Ad Scientiam partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and supporting.

  • Merck KGaAcoreStrategic or Co-development Partner · 13 November 2025Ad Scientiam and Merck KGaA are collaborating on a prospective, multicenter pilot study starting in 2026 across several European countries to evaluate an investigational software medical device combining a mobile application, wearable, and ePROs to collect digital measures in real-life unsupervised conditions for monitoring generalized myasthenia gravis (gMG).
  • SanoficoreStrategic or Co-development PartnerSanofi supported the MS-FLOWER pilot (62 MS patients across 4 US centers in Austin, St. Louis, Oklahoma City, New Orleans) and the MS-DETECT (NCT05816122) international clinical study. First results of MS-FLOWER to be presented at AAN 2026. Sanofi is a key partner in clinical validation of MSCopilot.
  • Vertex PharmaceuticalscoreStrategic or Co-development PartnerVertex Pharmaceuticals partnered with Ad Scientiam and the Société Française de Mucoviscidose on the Mucolab project, an ambitious innovation to improve at-home follow-up of cystic fibrosis patients through new respiratory digital biomarkers. Vertex is a global biotech company focused on cystic fibrosis treatments.
  • Société Française de Mucoviscidose (Cystic Fibrosis French Society)majorStrategic or Co-development PartnerThe Société Française de Mucoviscidose partnered with Ad Scientiam and Vertex Pharmaceuticals on the Mucolab project to develop respiratory digital biomarkers for at-home cystic fibrosis monitoring.
  • Microsoft (Azure Cloud)supportingTechnology or IntegrationAd Scientiam's website and data infrastructure are hosted on Microsoft's Azure cloud offering, geographically located within the European Union. Microsoft France is a certified health data host.
  • BSI (Notified Body)supportingOthersBSI is the Notified Body that granted Ad Scientiam its ISO 13485 'Medical devices - Quality management system' certification in August 2020.
  • ANSM (Agence nationale de sécurité du médicament et des produits de santé)supportingOthersAll Ad Scientiam Medical Devices are declared to the ANSM before being made available on the French market, in accordance with French medical device regulations.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Ad Scientiam competitors and assessment

Company assessment

Direct peers

  • Medable: Medable provides decentralized clinical trial technology and eCOA/ePRO solutions used by pharma sponsors to capture patient data outside clinic visits. Directly comparable to Ad Scientiam's B2B pharma clinical-trial enablement model and target customer base.
  • Koneksa Health: Koneksa develops digital biomarkers and remote patient monitoring tools used in clinical trials across therapeutic areas including neuroscience. Closely aligned to Ad Scientiam in technology (wearable/sensor-derived biomarkers), customer base (pharma), and validation model (clinical correlations).
  • VivoSense: VivoSense specializes in wearable sensors and digital endpoints for clinical trials and drug development, with regulatory-grade sensor data analytics. Direct competitor in digital biomarker/SaMD solutions sold to pharma sponsors.
  • Evidation Health: Evidation Health operates a digital health measurement platform that generates real-world evidence and digital biomarkers from consumer devices for pharma and life sciences clients. Highly comparable business model of consumer-grade data → regulatory-grade pharma evidence.

Emerging players

  • Aparito: Aparito provides remote patient monitoring and digital endpoint solutions for rare disease and specialty pharma clinical trials. Comparable in disease-monitoring SaMD positioning and pharma B2B model, though focused on smaller patient populations.
  • uMotif: uMotif offers a patient data capture platform (ePRO, eCOA) used in clinical trials across therapeutic areas. Adjacent peer in the decentralized clinical trial enablement space, with similar pharma customer base and disease-monitoring use cases.

Broad incumbents

  • Roche (Flatiron Health): Roche operates a broad digital health portfolio including Flatiron Health (oncology real-world evidence) and mySugr (diabetes monitoring). As a major MS drug manufacturer and Ad Scientiam trust-signal partner, Roche represents both a potential customer and a competitive threat via in-house digital biomarker programs.
  • Biogen: Biogen is a leading MS therapeutics company and listed as a trust-signal partner of Ad Scientiam. Competes indirectly through its own MS digital health initiatives and is simultaneously a potential enterprise customer for Ad Scientiam's MS monitoring solutions.
  • Novartis: Novartis operates digital biomarker and decentralized trial programs through its pharma R&D organization and partners like Science 37. Comparable in disease area (MS via Kesimpta) and broad SaMD ambitions.
  • Clario (ERT / Bioclinica): Clario (formed via ERT-Bioclinica merger) is a major provider of clinical trial endpoint technologies including eCOA, imaging, and digital biomarkers. Represents the broad incumbent player in the same pharma B2B SaMD-for-clinical-trials category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ad Scientiam social profiles

Digital presence

Ad Scientiam compliance and trust

Trust signal

Compliance3 records

Ad Scientiam financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ad Scientiam leadership team

Management profile

Number of profiles

Profiles5 records

Ad Scientiam subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ad Scientiam funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ad Scientiam M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ad Scientiam

What does Ad Scientiam do?

Ad Scientiam designs, validates, and commercializes Software as a Medical Device (SaMD) digital biomarkers that continuously measure disease progression in real-life conditions using smartphone sensor data processed by proprietary algorithms. Its flagship product MSCopilot® is a CE-marked (Class IIa) and FDA 510(k)-registered SaMD for self-assessment of Multiple Sclerosis patients, capturing more than 350 digital biomarkers across walking, vision, dexterity, and cognition. The portfolio also includes MuCopilot® for at-home cystic fibrosis monitoring and pipeline work in generalized myasthenia gravis with Merck KGaA.

Is Ad Scientiam a public or private company?

Ad Scientiam is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ad Scientiam founded?

Ad Scientiam was founded in 2013. It employs 51 to 100 people.

Where is Ad Scientiam based?

Ad Scientiam is headquartered in Paris, France, in the Europe region.

How does Ad Scientiam make money?

Two revenue lines are on record. B2B Licensing to Pharmaceutical Companies are the primary driver. The others are clinical Study Services.

Who are Ad Scientiam's main competitors?

Direct peers on record are Medable, Koneksa Health, VivoSense and Evidation Health. Emerging players are Aparito and uMotif. Broad incumbents are Roche (Flatiron Health), Biogen, Novartis and Clario (ERT / Bioclinica).

Does Ad Scientiam have an API?

No public API is recorded for Ad Scientiam.

What industry is Ad Scientiam in?

Ad Scientiam's product category is Medical Device Software (Digital Health). Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAd Scientiam Unveils Positive Interim 1-Year Longitudinal Results for MSCopilot® at EAN 2026Ad Scientiam presented interim results from the MS-DETECT and MS-FLOWER studies at EAN 2026, showing MSCopilot's digital biomarkers correlate with clinical standards over one year. The findings support MSCopilot's reliability in tracking disease progression and accelerating its deployment in US and European clinical workflows.EIN PresswireAd Scientiam launches U.S. subsidiary and expands deployment of MSCopilot® following FDA registrationAd Scientiam announced the creation of its U.S. subsidiary, Ad Scientiam Inc., to support MSCopilot deployment in the United States. The move follows FDA registration of MSCopilot under 510(k) exemption, enabling use in U.S. MS centers. The company plans rollouts in Europe and the UAE, with pilot results to be presented at the AAN conference.EIN PresswireAd Scientiam Collaborates with Merck KGaA to Launch Innovative Digital Clinical Study for Generalized Myasthenia GravisAd Scientiam has announced a collaboration with Merck KGaA to launch a prospective, multi-center pilot study in 2026 exploring the feasibility of an investigational software as a medical device for generalized Myasthenia Gravis (gMG), a rare autoimmune neuromuscular disease. The study will evaluate whether wearable technologies, smartphone-based functional tests, and electronic patient-reported outcomes (ePROs) can detect changes in disease trajectory in real-world, unsupervised conditions over a 12-month period across selected European countries. The results are intended to support the development of digital tools that could improve how neuromuscular disorders are monitored and managed, building toward larger clinical trials.AdscientiamTECHLIFE CAPITAL investit dans Ad ScientiamFrench digital health company Ad Scientiam has completed a €5 million fundraising round, with venture capital firm TechLife Capital joining as a reference shareholder. The funding will support the company's digital biomarkers portfolio expansion and exploration of new therapeutic areas. Ad Scientiam, which has operated for over 10 years developing medical technology for patients with serious and disabling diseases, aims to become the global leader in digital biomarkers.EIN PresswireTECHLIFE CAPITAL invests in AD SCIENTIAM, a pioneer in digital biomarkers for clinical & real-world patient monitoringTechLife Capital has invested in Ad Scientiam as lead investor to support the company's AI-powered digital biomarker platform for clinical and real-world patient monitoring of serious diseases. Founded in 2013, Ad Scientiam develops software medical devices that use smartphone-collected data and proprietary algorithms to monitor conditions including multiple sclerosis, rare diseases, and mental health disorders, serving major pharmaceutical companies. The investment, alongside existing shareholders Bedex et Associés and BioDigital Participations, will enable Ad Scientiam to expand its digital biomarker portfolio, enter new therapeutic areas, and consolidate its position as a global leader in the field.Cbs42TECHLIFE CAPITAL invests in AD SCIENTIAM, a pioneer in digital biomarkers for clinical & real-world patient monitoringTechLife Capital has made a growth equity investment as lead investor in Ad Scientiam, a Paris-based company specializing in AI-powered digital biomarkers for continuous patient monitoring of serious diseases including multiple sclerosis, rare diseases, and mental health conditions. The investment will enable Ad Scientiam to expand its portfolio of digital biomarkers and software medical devices, enter new therapeutic areas, and implement new commercialization models throughout the drug lifecycle. Ad Scientiam, founded in 2013 and supported by existing shareholders Bedex et Associés and BioDigital Participations, works with major pharmaceutical companies and has launched MSCopilot, the first CE-marked software medical device for multiple sclerosis self-assessment.AstrazenecaDigital biomarkers: a new era in rare neurological disease and beyondAlexion's SVP of Global Medical Affairs, Christophe Hotermans, described how digital biomarkers from wearables, implants and digestibles can continuously monitor rare neurological conditions, citing over 10,000 rare diseases affecting more than 400 million people. Alexion is collaborating with mobile health firm Ad Scientiam on NMOSDCoPilot and ME&MG apps for neuromyelitis optica spectrum disorder and generalised myasthenia gravis, to be clinically validated against gold standards.EscpFrom blockchain to digital biomarkers: opportunities and challenges in health techClarissa Gorin, head of medical affairs at the Parisian startup Ad Scientiam, discusses the potential of digital biomarkers and AI to augment healthcare practices and improve clinical research. She highlights challenges in health tech adoption, including patient skepticism regarding tool reliability and issues with diversity in clinical trials that may lead to ineffective treatments for minority populations.GlobeNewswireAd Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological DiseasesAd Scientiam launched two programs to develop and validate digital biomarkers for self-assessment of generalized myasthenia gravis and neuromyelitis optica spectrum disorders. The programs leverage five years of assets and are supported by Alexion and AstraZeneca Rare Disease. Clinical validation against gold standards will inform a digital medical device for patient self-assessment.